Last reviewed · How we verify
[14C] BMS-986278 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
[14C] BMS-986278 ([14C] BMS-986278) — Bristol-Myers Squibb.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| [14C] BMS-986278 TARGET | [14C] BMS-986278 | Bristol-Myers Squibb | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- [14C] BMS-986278 CI watch — RSS
- [14C] BMS-986278 CI watch — Atom
- [14C] BMS-986278 CI watch — JSON
- [14C] BMS-986278 alone — RSS
Cite this brief
Drug Landscape (2026). [14C] BMS-986278 — Competitive Intelligence Brief. https://druglandscape.com/ci/14c-bms-986278. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab